Gainers
- Sharps Technology STSS shares increased by 84.2% to $6.89 during Wednesday's regular session. The company's market cap stands at $7.0 million.
- Cellectar Biosciences CLRB stock increased by 61.52% to $0.45. The market value of their outstanding shares is at $20.6 million.
- Hoth Therapeutics HOTH shares increased by 44.59% to $1.33. The company's market cap stands at $17.5 million.
- ModivCare MODV stock moved upwards by 39.58% to $2.68. The market value of their outstanding shares is at $38.4 million.
- Rallybio RLYB shares rose 35.87% to $0.4. The company's market cap stands at $16.6 million.
- Cyclacel Pharmaceuticals CYCCP shares rose 30.0% to $5.2.
Losers
- Reshape Lifesciences RSLS stock declined by 28.1% to $4.85 during Wednesday's regular session. The company's market cap stands at $3.5 million.
- Neogen NEOG shares decreased by 23.22% to $4.61. The company's market cap stands at $999.4 million.
- NuCana NCNA stock fell 22.75% to $0.05. As per the news, the Q1 earnings report came out 2 days ago.
- Moleculin Biotech MBRX stock fell 21.57% to $0.66. The company's market cap stands at $9.3 million.
- Conduit Pharmaceuticals CDT shares fell 18.27% to $2.64. The market value of their outstanding shares is at $2.1 million.
- Lyra Therapeutics LYRA shares declined by 17.92% to $22.64. The market value of their outstanding shares is at $30.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
CDTConduit Pharmaceuticals Inc
$2.10-0.02%
Edge Rankings
Momentum
6.28
Price Trend
Short
Medium
Long
CLRBCellectar Biosciences Inc
$5.400.93%
CYCCPCyclacel Pharmaceuticals Inc
$5.309.50%
HOTHHoth Therapeutics Inc
$1.321.54%
LYRALyra Therapeutics Inc
$8.494.30%
MBRXMoleculin Biotech Inc
$0.5651-11.3%
MODVModivCare Inc
$3.091.31%
NCNANuCana PLC
$0.060912.8%
NEOGNeogen Corp
$5.221.95%
RLYBRallybio Corp
$0.5100-2.67%
RSLSReshape Lifesciences Inc
$2.38-12.8%
STSSSharps Technology Inc
$6.170.16%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.